On May 8, 2025 Takeda (TOKYO:4502/NYSE:TAK) reported financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management (Press release, Takeda, MAY 8, 2025, View Source [SID1234652790]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year.
FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE generic impact, continued efficiency savings and investment in R&D and launch preparation for Takeda’s late-stage pipeline.
Takeda chief executive officer, Christophe Weber, commented:
"Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Launch Products portfolio and the ability of our multi-year efficiency program to deliver meaningful cost savings.
"FY2025 will be a pivotal year as we invest in launch readiness for the late-stage pipeline, which will contribute to our broadly flat Core Operating Profit outlook for FY2025 but will be key to achieving Takeda’s long-term growth potential."
Takeda chief financial officer, Milano Furuta, commented:
"Takeda’s success in delivering revenue and Core Operating Profit growth in FY2024 and our outlook for broadly flat revenue and profit in FY2025, demonstrates our ability to manage through one of the largest generic impacts on our business in Takeda’s history while progressing a highly promising late-stage pipeline. Our performance and outlook speak to the strength of our Growth & Launch Products, our innovative pipeline and the resilience of our organization as a whole.
"Takeda is now at an inflection point, with multiple anticipated Phase 3 data readouts this fiscal year, and I’m excited about our growth trajectory."
FINANCIAL HIGHLIGHTS for FY2024 Ended March 31, 2025
(Billion yen, except percentages and per share amounts)
FY2024
FY2023
vs. PRIOR YEAR
(Actual % change)
Revenue
4,581.6
4,263.8
+7.5%
Operating Profit
342.6
214.1
+60.0%
Net Profit
107.9
144.1
-25.1%
EPS (Yen)
68
92
-25.8%
Operating Cash Flow
1,057.2
716.3
+47.6%
Adjusted Free Cash Flow (Non-IFRS)
769.0
283.4
+171.3%
Core (Non-IFRS)
(Billion yen, except percentages and per share amounts)
FY2024
FY2023
vs. PRIOR YEAR
(Actual % change)
vs. PRIOR YEAR
(CER % change)
Revenue
4,579.8
4,263.8
+7.4%
+2.8%
Operating Profit
1,162.6
1,054.9
+10.2%
+4.9%
Margin
25.4%
24.7%
+0.6pp
―
Net Profit
775.6
756.8
+2.5%
-3.4%
EPS (Yen)
491
484
+1.5%
-4.3%
FY2025 Outlook
(Billion yen, except percentages and per share amounts)
Item
FY2025 FORECAST
FY2025
MANAGEMENT
GUIDANCE
Core Change at CER
(Non-IFRS)
Revenue
4,530.0
—
Core Revenue (Non-IFRS)
4,530.0
Broadly flat
Operating Profit
475.0
—
Core Operating Profit (Non-IFRS)
1,140.0
Broadly flat
Net Profit
228.0
—
EPS (Yen)
145
—
Core EPS (Yen) (Non-IFRS)
485
Broadly flat
Adjusted Free Cash Flow (Non-IFRS)
750.0-850.0
—
Annual Dividend per Share (Yen)
200
—
Additional Information About Takeda’s FY2024 Results
For more details about Takeda’s FY2024 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda’s FY2024 Q4 investor presentation (available at View Source)